Ftse Mib
33.739,90
-0,08%
DAX
19.848,77
-0,34%
S&P 500
6.040,04
1,10%
NASDAQ
20.031,13
1,35%
Bitcoin
98.634,64
-0,67%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Processa Pharmaceuticals Inc (PCSA) Processa Pharmaceuticals Inc (PCSA) Notizie

Processa Pharmaceuticals Inc

PCSA
0,8694
0,0322 (3,85%)
24 Dic 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
20/12/202422:31EDGAR2Form S-1 - General form for registration of securities under..
06/11/202422:00EDGAR2Form 8-K - Current report
30/10/202421:15GLOBEProcessa Pharmaceuticals Reports Third Quarter Business..
30/10/202421:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02/10/202422:36EDGAR2Form 8-K - Current report
02/10/202422:05GLOBEProcessa Pharmaceuticals Announces First Patient Dosed in..
18/9/202422:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/9/202422:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/9/202422:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/9/202414:00GLOBEProcessa Pharmaceuticals to Participate in Investor and..
28/8/202414:00EDGAR2Form 8-K - Current report
28/8/202414:00GLOBEProcessa Pharmaceuticals Provides Product Pipeline and..
19/8/202414:00GLOBEProcessa Pharmaceuticals Announces Positive Preclinical Data..
13/8/202422:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02/8/202423:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/8/202423:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/8/202423:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/8/202423:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/7/202414:00EDGAR2Form 8-K - Current report
30/7/202414:00GLOBEProcessa Pharmaceuticals Announces FDA Clearance of IND..
22/7/202423:59EDGAR2Form S-8 - Securities to be offered to employees in employee..
17/7/202414:00EDGAR2Form 8-K - Current report
17/7/202414:00GLOBEProcessa Pharmaceuticals Names Russell L. Skibsted as Chief..
11/6/202420:19EDGAR2Form DEFR14A - Revised definitive proxy soliciting materials
11/6/202414:20GLOBEProcessa Pharmaceuticals Announces Positive Efficacy Results..
29/5/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
28/5/202422:49EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
21/5/202422:13EDGAR2Form 8-K - Current report
21/5/202422:10EDGAR2Form S-3 - Registration statement under Securities Act of..
10/5/202422:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/5/202414:00GLOBEProcessa Pharmaceuticals to Participate in the EF Hutton..
30/4/202414:00GLOBEProcessa Pharmaceuticals Names Dr. Steven Cha Senior Vice..
11/4/202414:00GLOBEProcessa Pharmaceuticals Presents Two Abstracts at the AACR..
28/3/202413:15GLOBEProcessa Pharmaceuticals to Present at the MedInvest Biotech..
25/3/202413:15GLOBEProcessa Pharmaceuticals to Present Data at the American..
21/2/202423:25EDGAR2Form 8-K - Current report
21/2/202414:15GLOBEProcessa Pharmaceuticals to Present at the 2024 BIO CEO &..
14/2/202419:00GLOBEProcessa Pharmaceuticals to Present at The Winter Wrap-Up..
06/2/202414:30EDGAR2Form 8-K - Current report
06/2/202414:30GLOBEProcessa Pharmaceuticals Regains Compliance with Nasdaq..
02/2/202400:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/2/202422:22GLOBEProcessa Pharmaceuticals Announces Closing of $7.0 Million..
31/1/202422:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/1/202416:46EDGAR2Form 8-K - Current report
29/1/202422:15EDGAR2Form 424B4 - Prospectus [Rule 424(b)(4)]
26/1/202415:04GLOBEProcessa Pharmaceuticals Announces Pricing of $7.0 Million..
25/1/202414:35EDGAR2Form 8-K - Current report
25/1/202414:30GLOBEProcessa Pharmaceuticals Announces Successful Completion of..
19/1/202414:00EDGAR2Form 8-K - Current report
19/1/202413:45GLOBEProcessa Pharmaceuticals Announces Expansion of NGC-Cap..
Apertura: 0,8182 Min: 0,8182 Max: 0,88199
Chiusura: 0,8372

La tua Cronologia

NASDAQ
PCSA
Processa Pharmaceuticals
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network